← Leaderboards
Francisco Robert
University Of Alabama At Birmingham
$1,276,857
Attributed
$1,276,857
Total exposure
9
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $16.7K · FY2005–06$20K$15K$10K$5K$0
'05
'06
Funding mix
By agency
NIH$1,276,857 · 9
By mechanism
M01$1,276,857 · 9
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Jeannette Y. Lee$42,887,766
- Selwyn M Vickers$28,481,364
- Mansoor N Saleh$1,868,012
- Gautam N Bijur$1,229,171
- James A Bonner$1,167,061
Others in their field
Top investigators on “Neoplasm /Cancer Chemotherapy”
- Charles A Coltman · Southwest Oncology Group$171,655,324
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Philip J Disaia · University Of California Irvine$41,530,194
- Walter J Curran · Thomas Jefferson University$37,520,030
- Samuel A Wells · Duke University$32,148,803
- Gregory H Reaman · National Childhood Cancer Foundation$19,436,422
Research focus
Neoplasm /Cancer ChemotherapyHuman Therapy EvaluationHuman SubjectClinical ResearchNonsmall Cell Lung CancerClinical TrialsAntineoplasticsDosageDrug Screening /EvaluationDrug Adverse EffectClinical Trial Phase IPharmacokineticsCombination ChemotherapyHead /Neck NeoplasmRenal Cell CarcinomaIntravenous AdministrationKidney NeoplasmsMesotheliomaMetastasisMonoclonal AntibodyCamptothecinNeoplastic GrowthNeoplastic ProcessBladder Neoplasm
Grant awards (20)
PHASE I DEXAMETHASONE/CARBOPLATIN/GEMCITABINE UNTREATED IIIB/IV NSCLC$1,880
M01 · FY2006 · RR · contact PI
PHASE I DEXAMETHASONE/CARBOPLATIN/GEMCITABINE UNTREATED IIIB/IV NSCLC$16,738
M01 · FY2005 · RR
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA$175,256
M01 · FY2002 · RR
PNU 214936 IN ADVANCED NON SMALL CELL LUNG CANCER$175,256
M01 · FY2002 · RR
EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA$175,256
M01 · FY2002 · RR
90YCC49 MONOCLONAL ANTIBODY IN ADVANCED NONSMALL CELL LUNG CANCER$0
M01 · FY2002 · RR
9 AMINOCAMPTOTHECIN IN SOLID TUMORS$0
M01 · FY2002 · RR
EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA$175,256
M01 · FY2001 · RR
PNU 214936 IN ADVANCED NON SMALL CELL LUNG CANCER$175,256
M01 · FY2001 · RR
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA$175,256
M01 · FY2001 · RR
9 AMINOCAMPTOTHECIN IN SOLID TUMORS$0
M01 · FY2001 · RR
90YCC49 MONOCLONAL ANTIBODY IN ADVANCED NONSMALL CELL LUNG CANCER$0
M01 · FY2001 · RR
EGFR ANTIBODY C225 WITH IRRADIATION IN ADVANCED HEAD &NECK SQUAMOUS CELL CANCER$29,529
M01 · FY2000 · RR
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA$29,529
M01 · FY2000 · RR
90YCC49 MONOCLONAL ANTIBODY IN ADVANCED NONSMALL CELL LUNG CANCER$29,529
M01 · FY2000 · RR
EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA$29,529
M01 · FY2000 · RR
CISPLATIN,DEXAMETHASONE &GEMCITABINE IN RELAPSED OR REFRACTORY NON HODGKIN'S$29,529
M01 · FY2000 · RR
PNU 214936 IN ADVANCED NON SMALL CELL LUNG CANCER$29,529
M01 · FY2000 · RR
9 AMINOCAMPTOTHECIN IN SOLID TUMORS$29,529
M01 · FY2000 · RR
TRIAL OF MMP INHIBITOR AG3340 W PACLITAXEL AND CARBOPLATIN IN NSC LUNG CANCER$0
M01 · FY2000 · RR